aTyr Pharma, Inc. (LIFE)
NASDAQ: LIFE · IEX Real-Time Price · USD
1.590
+0.020 (1.27%)
May 1, 2024, 4:00 PM EDT - Market closed
aTyr Pharma Revenue
In the year 2023, aTyr Pharma had annual revenue of $353.00K, a decrease of -96.60%.
Revenue (ttm)
$353.00K
Revenue Growth
-96.60%
P/S Ratio
305.16
Revenue / Employee
$6,304
Employees
56
Market Cap
107.72M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
Dec 31, 2022 | 10.39M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
Dec 31, 2019 | 422.00K | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sangamo Therapeutics | 176.23M |
FONAR | 102.42M |
CytomX Therapeutics | 101.21M |
TELA Bio | 58.45M |
Armata Pharmaceuticals | 4.53M |
Zentek | 25.27K |
GlycoMimetics | 10.00K |
LIFE News
- 4 weeks ago - aTyr Pharma to Participate in April Investor Conferences - GlobeNewsWire
- 6 weeks ago - aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results - GlobeNewsWire
- 2 months ago - aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants - GlobeNewsWire
- 3 months ago - aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor - GlobeNewsWire
- 6 months ago - aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 - GlobeNewsWire
- 6 months ago - aTyr Pharma to Present at November Investor Conferences - GlobeNewsWire
- 8 months ago - aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes - GlobeNewsWire